Cover Image
Market Research Report

Europe Active Pharmaceutical Ingredients Market Forecast 2019-2027

Published by Inkwood Research Product code 819214
Published Content info 93 Pages
Delivery time: 2-3 business days
Price
Back to Top
Europe Active Pharmaceutical Ingredients Market Forecast 2019-2027
Published: April 8, 2019 Content info: 93 Pages
Description

KEY FINDINGS

The pharmaceutical drug industry across the world is growing by leaps and bounds at present and is currently valued in billions approximately. The coveted companies in the market design the required drugs which predominantly contains the carrier substances and the active chemical substances that work in treating the condition known as the 'Active Pharmaceutical Ingredients' or API in short.

The Europe market for active pharmaceutical ingredients is on an exceptional upsurge in recent years since the region includes the developed countries in the likes of Germany, France, UK, etc. The regional market is expected to have an escalated growth, quantified by Inkwood Research as per the market analysis, to be around 5.75% CAGR by the end of 2027. The forecasting period is considered to be from 2019 to 2027, and 2018 is considered to be the base year for the market analysis.

MARKET INSIGHTS

The major economies that influence the market growth for APIs in the Europe region are the United Kingdom, France, Germany, Italy, Spain and the remaining countries collectively constituting the Rest of Europe regional segment.

In the United Kingdom, the presence of highly established healthcare infrastructure coupled with the high rate of cancer prevalence among the patient pool are the key driving factors for the API market. According to the Cancer Research United Kingdom, there are more than XX thousands of new cancer cases in the UK every year, which has escalated the adoption of the cancer drugs turbulently in the country.

COMPETITIVE INSIGHTS

Aurobindo Pharma, Lonza Group AG, Bayer AG, Novartis, Sun Pharmaceuticals Industries, Ltd., Merck & Co., Inc., Albemarle Corporation, Teva Pharmaceutical Industries, Ltd., Cipla, Mylan N.V., Dr. Reddy's Laboratories, Abbvie, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb, and Eli Lilly and Company are the major companies mentioned in the report.

Table of Contents
Product Code: 24573

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP-DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. INNOVATIVE APIS HOLDS THE LARGEST MARKET SHARE IN TERMS OF ACTIVE PHARMACEUTICAL INGREDIENTS TYPE
    • 3.2.2. MERCHANT APIS ARE THE FASTEST GROWING MANUFACTURERS
    • 3.2.3. BIOTECH IS THE FASTEST GROWING SYNTHESIS SEGMENT
    • 3.2.4. ONCOLOGY IS THE MAJORLY USED APPLICATION

4. MARKET DYNAMICS

  • 4.1. MARKET SCOPE & DEFINITION
  • 4.2. MARKET DRIVERS
    • 4.2.1. GROWING GERIATRIC POPULATION
    • 4.2.2. GROWING PREVALENCE OF INFECTIOUS DISEASES AND HOSPITAL ACQUIRED INFECTIONS
    • 4.2.3. INCREASING INCIDENCE OF AGE-RELATED DISEASES
  • 4.3. MARKET RESTRAINTS
    • 4.3.1. HIGH COST OF INVESTMENT AND PRODUCTION COST
    • 4.3.2. AGGRESSIVE COMPETITION AMONG API MANUFACTURERS
  • 4.4. MARKET OPPORTUNITIES
    • 4.4.1. GAINING POPULARITY FOR TARGETED THERAPY
    • 4.4.2. GROWING PREFERENCE FOR OUTSOURCING APIS
    • 4.4.3. IMPLEMENTING MEASURES AGAINST COUNTERFEIT DRUGS
  • 4.5. MARKET CHALLENGES
    • 4.5.1. STRINGENT GOVERNMENT REGULATIONS
    • 4.5.2. AVAILABILITY OF COUNTERFEIT PRODUCTS

5. MARKET BY TYPES

  • 5.1. GENERIC APIS
  • 5.2. INNOVATIVE APIS

6. MARKET BY MANUFACTURERS

  • 6.1. CAPTIVE APIS
  • 6.2. MERCHANT APIS

7. MARKET BY SYNTHESIS

  • 7.1. BIOTECH
    • 7.1.1. MONOCLONAL ANTIBODIES
    • 7.1.2. RECOMBINANT PROTEINS
    • 7.1.3. VACCINES
  • 7.2. SYNTHETIC

8. MARKET BY APPLICATION

  • 8.1. CARDIOVASCULAR DISEASE
  • 8.2. ONCOLOGY
  • 8.3. CNS AND NEUROLOGICAL DISORDERS
  • 8.4. ORTHOPEDIC DISORDERS
  • 8.5. ENDOCRINOLOGY
  • 8.6. PULMONOLOGY
  • 8.7. GASTROINTESTINAL DISORDERS
  • 8.8. NEPHROLOGY
  • 8.9. OPHTHALMOLOGY
  • 8.10. OTHER APPLICATION

9. KEY ANALYTICS

  • 9.1. PORTER'S FIVE FORCES MODEL
    • 9.1.1. THREAT OF NEW ENTRANTS
    • 9.1.2. THREAT OF SUBSTITUTE
    • 9.1.3. BARGAINING POWER OF BUYERS
    • 9.1.4. BARGAINING POWER OF SUPPLIERS
    • 9.1.5. THREAT OF COMPETITIVE RIVALRY
  • 9.2. PESTEL ANALYSIS
  • 9.3. SUPPLY CHAIN ANALYSIS
  • 9.4. OPPORTUNITY MATRIX

10. GEOGRAPHICAL ANALYSIS

  • 10.1. EUROPE
    • 10.1.1. THE UNITED KINGDOM
    • 10.1.2. GERMANY
    • 10.1.3. FRANCE
    • 10.1.4. ITALY
    • 10.1.5. SPAIN
    • 10.1.6. REST OF EUROPE

11. COMPETITIVE LANDSCAPE

  • 11.1. MARKET POSITION ANALYSIS
  • 11.2. COMPANY PROFILES
    • 11.2.1. ABBVIE, INC.
    • 11.2.2. ALBEMARLE CORPORATION
    • 11.2.3. AUROBINDO PHARMA
    • 11.2.4. BAYER AG
    • 11.2.5. BOEHRINGER INGELHEIM GMBH
    • 11.2.6. BRISTOL-MYERS SQUIBB
    • 11.2.7. CIPLA
    • 11.2.8. DR. REDDY'S LABORATORIES
    • 11.2.9. ELI LILLY AND COMPANY
    • 11.2.10. LONZA GROUP AG
    • 11.2.11. MERCK & CO., INC.
    • 11.2.12. MYLAN N.V.
    • 11.2.13. NOVARTIS
    • 11.2.14. SUN PHARMACEUTICALS INDUSTRIES, LTD.
    • 11.2.15. TEVA PHARMACEUTICAL INDUSTRIES LTD.

LIST OF TABLES

  • TABLE 1 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • TABLE 2 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPES 2019-2027 ($ MILLION)
  • TABLE 3 EUROPE GENERIC APIS MARKET 2019-2027 ($ MILLION)
  • TABLE 4 EUROPE INNOVATIVE APIS MARKET 2019-2027 ($ MILLION)
  • TABLE 5 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURERS 2019-2027 ($ MILLION)
  • TABLE 6 EUROPE CAPTIVE APIS MARKET 2019-2027 ($ MILLION)
  • TABLE 7 EUROPE MERCHANT APIS MARKET 2019-2027 ($ MILLION)
  • TABLE 8 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY SYNTHESIS 2019-2027 ($ MILLION)
  • TABLE 9 EUROPE BIOTECH MARKET 2019-2027 ($ MILLION)
  • TABLE 10 EUROPE BIOTECH MARKET BY TYPES 2019-2027 ($ MILLION)
  • TABLE 11 EUROPE MONOCLONAL ANTIBODIES MARKET 2019-2027 ($ MILLION)
  • TABLE 12 EUROPE RECOMBINANT PROTEINS MARKET 2019-2027 ($ MILLION)
  • TABLE 13 EUROPE VACCINES MARKET 2019-2027 ($ MILLION)
  • TABLE 14 EUROPE SYNTHETIC MARKET 2019-2027 ($ MILLION)
  • TABLE 15 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY APPLICATION 2019-2027 ($ MILLION)
  • TABLE 16 EUROPE CARDIOVASCULAR DISEASE MARKET 2019-2027 ($ MILLION)
  • TABLE 17 EUROPE ONCOLOGY MARKET 2019-2027 ($ MILLION)
  • TABLE 18 EUROPE CNS AND NEUROLOGICAL DISORDERS MARKET 2019-2027 ($ MILLION)
  • TABLE 19 EUROPE ORTHOPEDIC DISORDERS MARKET 2019-2027 ($ MILLION)
  • TABLE 20 EUROPE ENDOCRINOLOGY MARKET 2019-2027 ($ MILLION)
  • TABLE 21 EUROPE PULMONOLOGY MARKET 2019-2027 ($ MILLION)
  • TABLE 22 EUROPE GASTROINTESTINAL DISORDERS MARKET 2019-2027 ($ MILLION)
  • TABLE 23 EUROPE NEPHROLOGY MARKET 2019-2027 ($ MILLION)
  • TABLE 24 EUROPE OPHTHALMOLOGY MARKET 2019-2027 ($ MILLION)
  • TABLE 25 EUROPE OTHER APPLICATION MARKET 2019-2027 ($ MILLION)
  • TABLE 26 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 27 ACTIVE PHARMACEUTICAL INGREDIENTS COMPANY MARKET POSITION ANALYSIS 2017

LIST OF FIGURES

  • FIGURE 1 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 2 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY TYPES 2018 & 2027 (%)
  • FIGURE 3 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GENERIC APIS 2019-2027 ($ MILLION)
  • FIGURE 4 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY INNOVATIVE APIS 2019-2027 ($ MILLION)
  • FIGURE 5 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY MANUFACTURERS 2018 & 2027 (%)
  • FIGURE 6 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY CAPTIVE APIS 2019-2027 ($ MILLION)
  • FIGURE 7 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MERCHANT APIS 2019-2027 ($ MILLION)
  • FIGURE 8 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY SYNTHESIS 2017 & 2027 (%)
  • FIGURE 9 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BIOTECH 2019-2027 ($ MILLION)
  • FIGURE 10 EUROPE BIOTECH MARKET BY MONOCLONAL ANTIBODIES 2019-2027 ($ MILLION)
  • FIGURE 11 EUROPE BIOTECH MARKET BY RECOMBINANT PROTEINS 2019-2027 ($ MILLION)
  • FIGURE 12 EUROPE BIOTECH MARKET BY VACCINES 2019-2027 ($ MILLION)
  • FIGURE 13 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY SYNTHETIC 2019-2027 ($ MILLION)
  • FIGURE 14 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY APPLICATION 2018 & 2027 (%)
  • FIGURE 15 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY CARDIOVASCULAR DISEASE 2019-2027 ($ MILLION)
  • FIGURE 16 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY ONCOLOGY 2019-2027 ($ MILLION)
  • FIGURE 17 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY CNS AND NEUROLOGICAL DISORDERS 2019-2027 ($ MILLION)
  • FIGURE 18 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY ORTHOPEDIC DISORDERS 2019-2027 ($ MILLION)
  • FIGURE 19 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY ENDOCRINOLOGY 2019-2027 ($ MILLION)
  • FIGURE 20 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY PULMONOLOGY 2019-2027 ($ MILLION)
  • FIGURE 21 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GASTROINTESTINAL DISORDERS 2019-2027 ($ MILLION)
  • FIGURE 22 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY NEPHROLOGY 2019-2027 ($ MILLION)
  • FIGURE 23 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY OPHTHALMOLOGY 2019-2027 ($ MILLION)
  • FIGURE 24 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY OTHER APPLICATION 2019-2027 ($ MILLION)
  • FIGURE 25 PORTER'S FIVE FORCE MODEL
  • FIGURE 26 THE UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 27 GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 28 FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 29 ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 30 SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 31 REST OF EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
Back to Top